An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00767585 |
Recruitment Status
:
Completed
First Posted
: October 7, 2008
Last Update Posted
: July 3, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Breast Cancer Osteoporosis |
Study Type : | Observational |
Estimated Enrollment : | 560 participants |
Observational Model: | Case Control |
Time Perspective: | Cross-Sectional |
Official Title: | An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice |
Study Start Date : | August 2008 |
Actual Study Completion Date : | June 2009 |

Group/Cohort |
---|
A:
70 women with hormone-dependent or hormone-independent early breast cancer that have completed their chemo- and/or radiotherapy just recently (up to 6 months after completion of therapy)
|
B
70 women with hormone-independent early breast cancer, 24-36 months after completion of chemo- and/or radiotherapy
|
C
70 women with hormone-independent early breast cancer, 54-66 months after completion of chemo- and/or radiotherapy
|
D
70 women with hormone-dependent early breast cancer, 24-36 months after initiation of tamoxifen therapy
|
E
70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy
|
F
70 women with hormone-dependent early breast cancer, 54-66 months after initiation of tamoxifen therapy
|
G
70 women with hormone-dependent early breast cancer, 54-66 months after initiation of aromatase inhibitors therapy
|
H
70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy following 24-36 months of initial tamoxifen therapy
|
- To determine the effect of aromatase inhibitors therapy on bone mineral density as measured by DEXA scan and compare it to the effects of tamoxifen and no hormonal therapy. [ Time Frame: once ]
- To determine the bone fracture rate in women on aromatase inhibitors therapy and compare it to fracture rates observed in the tamoxifen and the hormone-independent group. [ Time Frame: once ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years to 65 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Women aged 55-65 years, diagnosed with invasive early breast cancer: - Surgery, chemo- and/or radiotherapy concluded less than 6 months ago
- Women with hormone-independent breast cancer: - Surgery, chemo- and/or radiotherapy concluded before 24-36 months or 54-66 months
- Women with hormone-dependent breast cancer:- Adjuvant therapy with tamoxifen initiated before 24-36 and 54-66 months or - Adjuvant therapy with aromatase inhibitor initiated before 24-36 and 54-66 months or - Switch from tamoxifen to aromatase inhibitor initiated before 24-36 months
Exclusion Criteria:
- Women receiving active treatment for osteoporosis
- Women with any evidence of breast cancer recurrence

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00767585
Slovenia | |
Research Site | |
Ljubljana, Slovenia |
Principal Investigator: | Simona Borstnar, MD, PhD | Institute of Oncology Ljubljana |
Responsible Party: | Meta Jeras, Mr Ph, Regulatory and Medical Affairs Manager, AstraZeneca UK Limited, Branch Office in Slovenia |
ClinicalTrials.gov Identifier: | NCT00767585 History of Changes |
Other Study ID Numbers: |
NIS-OSI-DUM-2008/1 |
First Posted: | October 7, 2008 Key Record Dates |
Last Update Posted: | July 3, 2009 |
Last Verified: | July 2009 |
Keywords provided by AstraZeneca:
breast cancer aromatase inhibitors bone mineral density osteoporosis |
Additional relevant MeSH terms:
Fractures, Bone Bone Diseases, Metabolic Bone Diseases Breast Neoplasms Osteoporosis Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Musculoskeletal Diseases |
Metabolic Diseases Wounds and Injuries Aromatase Inhibitors Steroid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |